FDA Suicidality Reassessments Will Be Made At Division Level, Not Through Guidance
Executive Summary
Decisions on whether to add drugs or classes of drugs to a list FDA has published of investigational products that need suicidality assessments will be made at the division level, the agency says.
You may also be interested in...
Suicidality Screening For All New Drugs Still On The Table After Draft Guidance
FDA lists eight drug classes where it will recommend prospective assessment of suicidality risk, but it invites comments on broadening the criteria.
Singulair And Suicidality: FDA Finds No Immediate Link, But Review Continues
FDA is continuing to review a possible relationship between the use of Merck's Singulair (montelukast) and an increased risk of suicidality despite finding no association so far between leukotriene pathway drugs and mood behaviors
FDA: Suicide Risk For Users Of Pfizer’s Anti-Smoking Drug Chantix
Agency warning echoes changed label; so far, 34 suicides and 420 cases of suicidal thoughts.